This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   April 04, 2014

 




Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors
American Journal of Transplantation (login required)
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative, but existing regimens rely on steroids and have higher rejection rates. Experimentally, donor bone marrow and sirolimus promote belatacept's efficacy. To investigate a belatacept-based regimen without CNIs or steroids, authors transplanted recipients of live donor kidneys using alemtuzumab induction, monthly belatacept and daily sirolimus.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




SOCIETY NEWS


AST announces 2015 Grants Program and RFA
AST
AST's research program has supported transplantation by funding more than 200 research projects. Today, we're pleased to announce the new Request for Applications for 2015 research grants! Also new for 2015 is the AST Transplant Nursing Grant. Details on the RFA, grant criteria, application and eligibility requirements can be found here. Applications are due by Monday, Sept. 15.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


ESOT + AST: Partnering to bring you the best transplantation science
AST
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19
Madrid, Spain

Submit your clinical, translational and basic abstracts on Novel Immune Monitoring and/or Diagnostics and Immunosuppression Strategies. Submission Deadline: Sunday, June 29.

Long-term graft and patient survival are the key issues in transplantation. Outcomes are affected by individual immune risk and co-morbidities, as well as gender and race. The time is now to focus on improving outcomes through personalized medicine and finding the optimal combination of immunosuppressive drugs in the right dose for each patient.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




A discussion of risk in living kidney donors and other online education activities

The following webinars and journal club are scheduled for April, all are free to AST members and are available on demand after the live air date.
  • Journal Club on the role of Neuropilin-Semaphorin interactions in modulating Treg suppressor function: Wed., 4/9; register online
  • Fellows Webinar on Generic Immunosuppressants: Thurs., 4/10; register online
  • Discussion of Risk in Living Kidney Donors: Tues., 4/22; register online
AST also offers popular webinars on demand at www.myAST.org/T3 and at www.myAST.org/content/fellows-live-webinar-series, including understanding the new UNOS/OPTN kidney allocation policy!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured Advertisers


UCLA Immunogenetics Center


The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
University of Utah - Multi-Organ Transplant Surgeon

The University Of Utah Department Of Surgery is seeking applications for a faculty member to join the multi-organ transplant team at the assistant professor level. This is an opportunity to join an expanding program and a cohesive group of transplant surgeons focused on excellence. The candidate should be board certified in general surgery and have completed an ASTS approved transplantation surgery fellowship. Apply here
2013 USIEC Excellence Award Winner

OTTR is pleased to be recognized for Excellence in Software by USIEC and for receiving CIBMTR Certification. Please contact us at ottr.com to see how we can help you.


TRANSPLANT NEWS


Ureteral complications after hand-assisted laparoscopic living donor nephrectomy
Transplantation (login required)
Urological complications, namely ureteral leak and obstruction, remain a major source of morbidity after renal transplantation. Given that the existing literature on ureteral complications pertains mostly to deceased as opposed to living donors, authors aimed to assess the risk factors for ureteral complications solely after living donor nephrectomy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Post-transplant hip fracture rate declining
Renal & Urology News
Hip fractures remain an important complication following kidney transplantation, but the incidence of these fractures has decreased substantially since 1997, according to a new study. The study, led by Dr. Wolfgang C. Winkelmayer, ScD, associate professor of medicine and director of clinical research in the Division of Nephrology at Stanford University of School of Medicine in Palo Alto, Calif., included 69,740 patients who under kidney transplantation from 1997 to 2010.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab
Transplantation (login required)
Desensitization with intravenous immune globulin (IVIG) and rituximab improves transplantation rates. It is unclear if desensitization increases the risk of polyomavirus BK (BKV) viremia. Here, BKV viremia in HLA-sensitized patients after desensitization with IVIG and rituximab was analyzed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Ribavirin may treat hepatitis E infection in transplant recipients
Renal & Urology News
Ribavirin may be an effective form of monotherapy for solid-organ transplant patients with chronic hepatitis E virus (HEV) infection, French researchers reported in a study published online ahead of print in The New England Journal of Medicine. "To date, there is no established therapy for HEV infection," a research team led by Dr. Nassim Kamar, Ph.D., of Toulouse University, stated. "Here we report a combined case series from several transplantation centers in France, involving solid-organ transplant recipients infected with HEV who were treated with ribavirin alone."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    The role of donor-specific HLA alloantibodies in liver transplantation (American Journal of Transplantation)
Medical outcomes of adolescent live kidney donors (Pediatric Transplantation)
Transplantation genetics: current status and prospects (American Journal of Transplantation)
Stephen Harms named UNOS Chief Operating Officer (United Network for Organ Sharing)
National assessment of early biliary complications following liver transplantation: Incidence and outcomes (Liver Transplantation)

Don't be left behind. Click here to see what else you missed.


2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
Heptaology
Guidelines on Evaluation for Liver Transplantation were produced in 2005 by the American Association for the Study of liver Diseases. In the interim there have been major advances in the management of chronic liver disease, most notably in antiviral therapy for chronic viral hepatitis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Liver Transplantation (login required)
There is conflicting literature regarding the superiority of transarterial chemoembolization (TACE) versus bland transarterial embolization (TAE), and this has not been well studied before transplantation. Twenty-five TAE patients were matched in a 1:2 ratio with TACE patients by the initial radiographic tumor size and number in a retrospective, case-controlled study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
March 28, 2014
March 21, 2014
March 14, 2014
March 7, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063